The Technical Analyst
Select Language :
Xencor Inc [XNCR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Xencor Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Xencor Inc is listed at the  Exchange

-0.51% $22.31

America/New_York / 28 mar 2024 @ 11:30


FUNDAMENTALS
MarketCap: 1 363.29 mill
EPS: -2.08
P/E: -10.72
Earnings Date: May 05, 2024
SharesOutstanding: 61.12 mill
Avg Daily Volume: 0.739 mill
RATING 2024-03-27
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -10.72 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.82x
Company: PE -10.72 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$4.31
(-80.70%) $-18.00
Date: 2024-03-28
Expected Trading Range (DAY)

$ 21.04 - 23.58

( +/- 5.70%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-11 Kuch John J Sell 849 Common Stock
2024-03-11 Eckert Celia Sell 850 Common Stock
2024-03-11 Desjarlais John R Sell 1 280 Common Stock
2024-03-11 Dahiyat Bassil I Sell 2 741 Common Stock
2024-03-06 Gustafson Kurt A Buy 15 000 Common Stock
INSIDER POWER
62.15
Last 97 transactions
Buy: 2 670 677 | Sell: 459 713

Forecast: 13:09 - $22.08

Live Trading Signals (every 1 min)

Forecast 1: 11:39 - $22.30
Forecast 2: 12:29 - $22.11
Forecast 3: 13:09 - $22.08
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $22.31 (-0.51% )
Volume 0.0471 mill
Avg. Vol. 0.739 mill
% of Avg. Vol 6.38 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Xencor Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Xencor Inc

RSI

Intraday RSI14 chart for Xencor Inc

Last 10 Buy & Sell Signals For XNCR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$18.70N/AActive
Profile picture for
            Xencor Inc

XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Last 10 Buy Signals

Date Signal @
SETHUSDMar 28 - 11:223 585.80
KDPMar 28 - 11:28$30.72
EXCMar 28 - 11:28$37.40
ETHUSDMar 28 - 11:28$3 574.03
PODDMar 28 - 11:26$169.57
SFRXETHUSDMar 28 - 11:243 817.60
PSGUSDMar 28 - 11:235.30
ASRUSDMar 28 - 11:233.14
ARKMUSDMar 28 - 11:222.76
ZTUSDMar 28 - 11:13102.26

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.